Developing a highly specific and sensitive glucagon ELISA kit
Award amount
$224,670Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AVANTGEN INC
- Proposal award date
- 2015-09-01
- Contract end date
- 2016-08-31
- UEI
- WLNHKNPNT2M7
- Solicitation number
- DK14-008
- Topic code
- 200
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR FERRET BIOMARKERS.
- DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR INDIAN FLYING FOX (BAT) BIOMARKERS
- A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
- DEVELOPMENT OF RABBIT MONOCLONAL ANTIBODIES FOR FERRET BIOMARKERS
- DEVELOPMENT OF RAPID AND POINT-OF-CARE DIAGNOSTIC KIT FOR HEPATITIS C VIRUS DETECTION
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment
Research funding history
24 SBIR/STTR records share this UEI (2008–2025). Reported award amounts total $14,979,724. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services